|
Session 99
Poster Abstracts
Complex Drug Interactions
Monday, 1:30 - 3:30 pm
Poster Hall |
583
 |
Significant Decrease in TMC125 Exposures when Co-administered with Tipranavir Boosted with Ritonavir in Healthy Subjects
Monika Schöller*1, M Kraft2, R Hoetelmans1, V Vyncke1, K Vandermeulen1, M Peeters1, L Bastiaanse1, C Debroye1, B Woodfall1, and B Baeten1
1Tibotec, Mechelen, Belgium and 2Boehringer Ingelheim, Ingelheim, Germany |
584
|
Effect of Lopinavir and Ritonavir Dose Adjustments on the Pharmacokinetic Interaction between LPV/RTV and Tipranavir
Marianne Harris*1, S Ramirez1, R Joy1, E Phillips1, F Harris2, J Sabo3, M Kraft4, and J Montaner1
1BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada; 2Boehringer Ingelheim Ltd, Burlington, Canada; 3Boehringer Ingelheim Pharma, Ridgefield, CT, US; and 4Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany |
| 585 |
Beneficial Pharmacokinetic Interaction between Atazanavir and Lopinavir/Ritonavir
Paul Pham*1, T Parsons1, C Flexner1, L Vasist3, E Redpath1, E fuchs1, K Carson1, S Agarwala2, and P Barditch-Crovo1
1Johns Hopkins Univ, Baltimore, MD, US; 2Bristol-Myers Squibb, Plainsboro, NJ, US; and 3Univ of North Carolina at Chapel Hill, US |
586
|
Pharmacokinetics of Saquinavir with Low-dose Ritonavir or Atazanavir Twice Daily in Seronegative Volunteers: ASPIRE II
Jennifer King*1, S Paul Lundy2, T Kakuda3, S Becker4, and E Acosta1
1Univ of Alabama at Birmingham, US; 2Pharma Product Devt, Menlo Park, CA, US; 3Roche, Nutley, NJ, US; and 4AnorMed, Langley, Canada |
| 587 |
Pharmacokinetics of Once-daily Fosamprenavir 1400 mg plus Atazanavir 400 mg without Ritonavir in HIV-negative Subjects
Patrick Clay*1, P Anderson2, P Smith3, D Lein4, and A Glaros1
1Kansas City Univ of Med and Biosci, MO, US; 2Univ of Colorado Hlth Sci Sch of Pharm, Denver, US; 3Univ of Buffalo Sch of Pharm, NY, US; and 4Kansas City Free Hlth Clin, MO, US |
588
|
Pharmacokinetics and Pharmacodynamics of Combined Use of Lopinavir/ritonavir and Rosuvastatin in HIV-infected Patients
Manon Van Der Lee*1, M Vogel2, E Schippers3, J Rockstroh2, G Fätkenheuer4, C Wyen4, P Koopmans1, R Sankatsing5, P Reiss5, and D Burger1
1Radboud Univ Nijmegen Med Ctr, The Netherlands; 2Univ of Bonn, Germany; 3Univ Med Ctr Leiden, The Netherlands; 4Univ of Cologne, Germany; and 5Academic Med Ctr, Amsterdam, The Netherlands |
|
